S. Rostamnia et al. / Journal of Molecular Catalysis A: Chemical 374–375 (2013) 85–93
87
heated at 45 ◦C (initial temperature value) for 15–20 min under
irradiation of the ultrasonic in 10 mL EtOH. After completion of
the reaction (TLC) the solvent was removed under reduced pres-
filtered it for remove catalyst. The crude product was recrystal-
lized from ethyl acetate/n-hexane (3:5) to afford the pure product.
Products are known compounds, and their structures were deduced
by comparison of their physical and spectroscopic data with those
previously reported [2–12].
(75 MHz, CDCl3): 28.5, 28.7, 34.7, 38.0, 50.9, 64.3, 115.5, 115.8,
118.21, 127.7, 128.0, 128.9, 129.0, 132.2, 133.6, 134.6, 151.0, 154.4,
156.0, 192.1.
13-(4-chlorophenyl)-3,3-dimethyl-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione
(4i)
1H
NMR
(300.13 MHz, CDCl3): 1.20 (6 H, s), 2.33 (2 H, s), 3.20 and 3.40 (2
2
H, ABq, JHH 19.2 Hz), 6.41(1 H, s), 7.29–7.38 (4 H, m), 7.84–7.87
(2 H, m), 8.24–8.37 (2 H, m). 13C NMR (75 MHz, CDCl3): 28.4, 28.7,
34.6, 38.0, 50.6, 64.3, 118.0, 127.7, 128.0, 128.2, 128.5, 128.9, 129.7,
133.6, 134.5, 134.6, 134.9, 151.1, 154.3, 155.9, 192.1.
3,3-dimethyl-13-phenyl-2,3,4,6,11,13-hexahydro-1H-
indazolo[1,2-b]phthalazine-1,6,11-trione
(4a):
1H
NMR
(300.13 MHz, CDCl3): 1.22 (6 H, s), 2.34 (2 H, s), 3.21–3.45 (2
2
H, ABq, JHH 18.9 Hz), 6.45 (1 H, s), 7.27–7.43 (4 H, m), 7.83–7.86
2.4. General procedure for synthesis of alkyl 4-(aryl)-2,7,7-
trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate
derivatives 8
(2 H, m), 8.25–8.37 (2 H, m). 13C NMR (75 MHz, CDCl3): 28.5, 28.7,
34.7, 38.0, 50.9, 64.9, 118.6, 127.1, 127.7, 127.9. 128.7, 28.9, 129.0,
133.5, 134.5, 136.4, 150.8, 154.3, 156.0, 192.1.
13-(2-chlorophenyl)-3,3-dimethyl-2,3,4,6,11,13-hexahydro-
To a solution of EtOH (10 mL) was added -diketon (3 mmol),
aldehyde (3.3 mmol), dimedone (3 mmol), ammonium acetate
(4 mmol) and SBA-15/SO3H (0.07 g, ∼4 mol%). The mixture was
sonicated at room temperature (initial temperature value) for
appropriate time and reaction progress monitored by TLC. After
completion of the reaction, catalyst was filtrate by centrifuge and
then the product recrystallized in ethanol. The products are known
and were identified by their physical and spectral data.
Methyl 2,7,7-trimethyl-5-oxo 4-phenyl -1,4,5,6,7,8-hexahydro-
3-quinolinecarboxylate (8a) 1H NMR (300.13 MHz, CDCl3): 0.94 (s,
3 H), 1.09 (s, 3 H), 2.11–2.40 (m, 8 H), 3.62 (s, 3 H), 5.08 (s, 1 H),
7.08–7.31 (m, 5 H).
1H-indazolo[1,2-b]phthalazine-1,6,11-trione
(4b)
1H
NMR
(300.13 MHz, CDCl3): 1.21 (6 H, s), 2.32 (2 H, s), 3.20–3.44 (2
2
H, ABq, JHH 20.3 Hz), 6.68 (1 H, s), 7.21–7.33 (4 H, m), 7.84–7.87
(2 H, m), 8.24–8.39 (2 H, m). 13C NMR (75 MHz, CDCl3): 28.4, 28.8,
34.8, 38.0, 50.9, 64.1, 127.2, 127.7, 128.1, 128.7, 129.0, 129.8, 130.5,
133.0, 133.6, 134.5, 151.8, 154.2, 156.2, 192.1.
13-(2-bromophenyl)-3,3-dimethyl-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine 1,6,11-trione (4c) 1H NMR
(300.13 MHz, CDCl3): 1.22 (6 H, s), 2.32 (2 H, s), 3.21–3.43 (2
2
H, ABq, JHH 18.9 Hz), 6.71 (1 H, s), 7.12–7.54 (4 H, m), 7.84–7.87
(2 H, m), 8.24–8.38 (2 H, m). 13C NMR (75 MHz, CDCl3): 28.6, 28.7,
34.6, 38.0, 50.9, 65.7, 126.9, 127.7, 127.8, 128.0, 128.7, 129.1, 130.1,
133.6, 133.9, 134.5, 151.9, 154.3, 156.2, 192.0.
Methyl 4-(2-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydro-3-quinolinecarboxylate (8b) IR (KBr vmax/cm−1): 3289,
3,3-dimethyl-13-(2-nitrophenyl)-2,3,4,6,11,13-hexahydro-
2951, 1707, 1654, 1608, 1490, 1222, 1080, 1034, 827, 773, 540. 1
H
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (4d) 1H NMR
NMR (300.13 MHz, CDCl3): 0.91 (s, 3 H), 1.07 (s, 3 H), 2.04–2.36 (m,
7 H), 3.57 (s, 3 H), 5.38 (s, 1 H), 6.81 (s, 1 H), 7.00–7.34 (m, 4 H).
13C NMR (75 MHz, CDCl3): 19.19, 27.15, 29.37, 32.54, 35.61, 40.96,
50.62, 50.83, 105.17, 111.37, 126.42, 127.26, 129.61, 131.64, 131.64,
133.10, 143.87, 144.33, 148.92, 167.91, 195.51.
Methyl 4-(2-methylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydro-3-quinolinecarboxylate (8c) IR (KBr vmax/cm−1) 3282,
3189, 3071, 2956, 1693, 1644, 1484. 1H NMR (300.13 MHz, CDCl3):
0.95 (s, 3 H), 1.09 (s, 3 H), 2.11–2.44 (m, 8 H), 3.62 (s, 3 H), 5.03 (s,
1 H), 5.90 (s, 1 H), 7.00–7.19 (m, 4 H). 13C NMR (75 MHz, CDCl3):
27.21, 29.37, 35.79, 41.23, 51.03, 127.66, 128.73.
Methyl 4-(4-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydro-3-quinolinecarboxylate (8d) IR (KBr vmax/cm−1): 3288,
2958, 1645, 1610, 1391, 1218, 1074, 1012, 840, 775, 538. 1H NMR
(300.13 MHz, CDCl3): 0.92 (s, 3 H), 1.08 (s, 3 H), 2.10–2.32 (m, 4 H),
2.39 (s, 3 H), 3.61 (s, 3 H, OCH3), 5.04 (s, 1 H), 6.2 (s, 1 H), 7.15–7.27
(m, 4 H). 13C NMR (75 MHz, CDCl3): 19.45, 27.06, 28.09, 28.24, 29.42,
32.71, 35.95, 41.05, 50.63, 51.08, 105.40, 111.90, 128.10, 129.24,
131.64, 143.98, 145.36, 148.23, 167.67, 195.57.
2
(300.13 MHz, CDCl3): 1.18 (6 H, s), 2.26–2.38 (2 H, ABq, JHH
2
19.2 Hz), 3.21–3.47 (2 H, ABq, JHH 20.3 Hz), 7.32–7.57 (4 H, m),
7.82–7.93 (2 H, m), 8.22–8.37 (2 H, m). 13C NMR (75 MHz, CDCl3):
28.5, 28.6, 34.6, 38.0, 50.7, 60.5, 116.8, 125.1, 127.7, 128.1, 128.6,
129.0, 129.5, 130.7, 133.1, 133.8, 134.7, 149.2, 152.0, 154.4, 156.0,
191.9.
3,3-dimethyl-13-(3-nitrophenyl)-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione
(4e)
1H
NMR
(300.13 MHz, CDCl3): 1.23 (6 H, s), 2.35 (2 H, s), 3.24–3.47 (2
H, ABq, 2JHH 19.2 Hz), 6.52 (1 H, s), 7.53–7.59 (1 H, m), 7.87–7.91 (3
H, m), 8.15–8.18 (2 H, m), 8.24–8.40 (2 H, m). 13C NMR (75 MHz,
CDCl3): 28.4, 28.7, 34.8, 38.0, 50.8, 64.2, 117.2, 121.5, 123.7, 127.7,
128.3, 128.6, 128.9, 129.7, 133.9, 134.3, 134.8, 138.6, 148.5, 151.8,
154.7, 155.9, 192.1.
13-(3-bromophenyl)-3,3-dimethyl-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione
(4f)
1H
NMR
(300.13 MHz, CDCl3): 1.21 (6 H, s), 2.34 (2 H, s), 3.20–3.44 (2
H, ABq, 2JHH 19.2 Hz), 6.39 (1 H, s), 7.19–7.24 (1 H, m), 7.40–7.48 (3
H, m), 7.85–7.88 (2 H, m), 8.25–8.38 (2 H, m). 13C NMR (75 MHz,
CDCl3): 28.5, 28.6, 34.7, 38.0, 50.9, 64.2, 117.9, 122.8, 126.3, 127.8,
128.1, 128.9, 129.0, 129.8, 130.2, 131.9, 133.7, 134.7, 138.7, 151.2,
154.4, 156.0, 192.0.
Methyl
1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate
max/cm−1): 3274, 2960, 1705, 1648, 1608, 1494. 1H NMR
4-(4-methoxyphenyl)-2,7,7-trimethyl-5-oxo-
(8e) IR (KBr
v
(300.13 MHz, CDCl3): 0.94 (s, 3 H), 1.08 (s, 3 H), 2.10–2.38 (m, 7
H), 3.62 (s, 3 H), 3.74 (s, 3 H), 5.01 (s, 1 H), 5.95 (s, 1 H), 6.74 (d,
J = 8.7 Hz, 2 H), 7.21 (d, J = 8.7 Hz, 2 H). 13C NMR (75 MHz, CDCl3):
19.52, 27.16, 29.41, 35.40, 41.22, 50.68, 51.02, 55.10, 113.36,
128.75.
Ethyl 4-(2-methylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydro-3-quinolinecarboxylate (8f) IR (KBr vmax/cm−1): 3245,
3078, 2958, 1701, 1600. 1H NMR (300.13 MHz, CDCl3): 0.95 (s, 3
H), 1.07 (s, 3 H), 1.22 (t, J = 6.9 Hz, 3 H), 2.13–2.34 (m, 10 H), 4.06
(q, J = 6.9 Hz, 2 H), 5.02 (s, 1 H), 6.30 (s, 1 H), 7.00–7.27 (m, 4 H).
13C NMR (75 MHz, CDCl3): 14.20, 19.31, 21.04, 27.21, 29.34, 32.74,
36.11, 41.05, 50.27, 59.85, 106.84, 112.01, 127.87, 128.63, 135.46,
143.08, 143.94, 167.38, 195.38.
3,3-dimethyl-13-(4-nitrophenyl)-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione
(4g)
1H
NMR
(300.13 MHz, CDCl3): 1.18 (6 H, s), 2.33 (2H, s), 3.22–3.44 (2
H, ABq, 2JHH 18.9 Hz), 6.50 (1 H, s),7.60 (2 H, m), 7.86–7.89 (2 H, m),
8.17–8.25 (3 H, m), 8.35–8.39 (1 H, m). 13C NMR (75 MHz, CDCl3):
28.4, 28.7, 34.7, 38.0, 50.8, 64.8, 117.3, 124.0, 127.8, 128.1, 128.2,
128.6, 128.9, 133.9, 134.8, 143.4, 147.8, 151.7, 154.5, 155.9, 192.0.
13-(4-fluorophenyl)-3,3-dimethyl-2,3,4,6,11,13-hexahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (4h) 1H NMR
(300.13 MHz, CDCl3): 1.21 (6 H, s), 2.34 (2 H, s), 3.20–3.44 (2
2
3
H, ABq, JHH 19.2 Hz), 6.43 (1 H, s), 7.02 (2 H, t, JHH 5.4 Hz),
7.38–7.43 (2 H, m), 7.84–7.87 (2 H, m), 8.25–8.37 (2 H, m). 13C NMR